Repeated high-dose (5 × 108 TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbits

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 7, 2016, Pages 1795-1801

  Tree, Julia A ^a   Hall, Graham ^a   Rees, Peter ^b   Vipond, Julia ^a   Funnell, Simon G P ^a   Roberts, Allen D ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Department of Bioanalytical Services   (United States)

Author keywords

IMVAMUNE; MVA; rabbits; smallpox; toxicology; vaccine

Indexed keywords

SMALLPOX VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BIOTERRORISM; BLOOD BIOCHEMISTRY; BLOOD CHEMISTRY; BODY WEIGHT; CLINICAL CHEMISTRY; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FEMALE; FOOD INTAKE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; IMMUNOGENICITY; LEUKOCYTE COUNT; MALE; MONOCYTE; NEUTROPHIL; NEW ZEALAND; NONHUMAN; ORGAN WEIGHT; PHASE 2 CLINICAL TRIAL (TOPIC); RABBIT; RETICULOCYTE COUNT; SEROCONVERSION; SMALLPOX VIRUS; TISSUE CULTURE INFECTIOUS DOSE 50; TOXICITY; TOXICOLOGY; VIRUS CONCENTRATION; ANIMAL; BLOOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; LEPORIDAE; PATHOLOGY; PRECLINICAL STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIBODIES, VIRAL; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INJECTIONS, SUBCUTANEOUS; MALE; RABBITS; SMALLPOX VACCINE; VACCINES, ATTENUATED;

EID: 84978683043     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1134070     Document Type: Article

References (24)

1. A.W.Artenstein, J.D.Grabenstein. Smallpox vaccines for biodefense: need and feasibility. Expert Rev Vaccines 2008; 7:1225-37; PMID:18844596; http://dx.doi.org/10.1586/14760584.7.8.1225
2. P.K.Russell. Vaccines in civilian defense against bioterrorism. Emerg Infect Dis 1999; 5:531-3; PMID:10458959; http://dx.doi.org/10.3201/eid0504.990413
3. D.A.Henderson, T.V.Inglesby, J.G.Bartlett, M.S.Ascher, E.Eitzen, P.B.Jahrling, J.Hauer, M.Layton, J.McDade, M.T.Osterholm, et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. Jama 1999; 281:2127-37; PMID:10367824; http://dx.doi.org/10.1001/jama.281.22.2127
4. S.E.Frey, F.K.Newman, J.S.Kennedy, V.Sobek, F.A.Ennis, H.Hill, L.K.Yan, P.Chaplin, J.Vollmar, B.R.Chaitman, et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007; 25:8562-73; PMID:18036708; http://dx.doi.org/10.1016/j.vaccine.2007.10.017
5. W.Metzger, B.G.Mordmueller. Vaccines for preventing smallpox. Cochrane Database Syst Rev 2007 Jul 18; (3):CD004913; PMID:17636779
6. J.M.Lane, F.L.Ruben, J.M.Neff, J.D.Millar. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122:303-9; PMID:4396189; http://dx.doi.org/10.1093/infdis/122.4.303
7. T.N.Thomas, S.Reef, L.Neff, M.M.Sniadack, G.T.Mootrey. A review of the smallpox vaccine adverse events active surveillance system. Clin Infect Dis 2008; 46 Suppl 3:S212-20; PMID:18284361; http://dx.doi.org/10.1086/524742
8. A.R.Kemper, M.M.Davis, G.L.Freed. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002; 5:84-90; PMID:11990216
9. P.L.Earl, J.L.Americo, L.S.Wyatt, L.A.Eller, J.C.Whitbeck, G.H.Cohen, R.J.Eisenberg, C.J.Hartmann, D.L.Jackson, D.A.Kulesh, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004; 428:182-5; PMID:15014500; http://dx.doi.org/10.1038/nature02331
10. H.Stickl, V.Hochstein-Mintzel, A.Mayr, H.C.Huber, H.Schafer, A.Holzner. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr 1974; 99:2386-92; PMID:4426258; http://dx.doi.org/10.1055/s-0028-1108143
11. A.Mayr, H.Stickl, H.K.Muller, K.Danner, H.Singer. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B 1978; 167:375-90; PMID:219640
12. J.S.Kennedy, R.N.Greenberg. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Exp Rev Vaccines 2009; 8:13-24; PMID:19093767; http://dx.doi.org/10.1586/14760584.8.1.13
13. S.E.Frey, P.L.Winokur, R.A.Salata, S.S.El-Kamary, C.B.Turley, E.B.Walter, Jr., C.M.Hay, F.K.Newman, H.R.Hill, Y.Zhang, et al. Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using different strategies for a post event scenario. Vaccine 2013; 31:3025-33; PMID:23664987; http://dx.doi.org/10.1016/j.vaccine.2013.04.050
14. J.Vollmar, N.Arndtz, K.M.Eckl, T.Thomsen, B.Petzold, L.Mateo, B.Schlereth, A.Handley, L.King, V.Hulsemann, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006; 24:2065-70; PMID:16337719; http://dx.doi.org/10.1016/j.vaccine.2005.11.022
15. A.von Krempelhuber, J.Vollmar, R.Pokorny, P.Rapp, N.Wulff, B.Petzold, A.Handley, L.Mateo, H.Siersbol, H.Kollaritsch, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010; 28:1209-16; PMID:19944151; http://dx.doi.org/10.1016/j.vaccine.2009.11.030
16. G.J.Hatch, V.A.Graham, K.R.Bewley, J.A.Tree, M.Dennis, I.Taylor, S.G.Funnell, S.R.Bate, K.Steeds, T.Tipton, et al. Assessment of the Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in Cynomolgus Macaques. J Virol 2013; 87:7805-15; PMID:23658452; http://dx.doi.org/10.1128/JVI.03481-12
17. M.S.Keckler, D.S.Carroll, N.F.Gallardo-Romero, R.R.Lash, J.S.Salzer, S.L.Weiss, N.Patel, C.J.Clemmons, S.K.Smith, C.L.Hutson, et al. Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges. J Virol 2011; 85:7683-98; PMID:21632764; http://dx.doi.org/10.1128/JVI.02174-10
18. N.L.Garza, J.M.Hatkin, V.Livingston, D.K.Nichols, P.J.Chaplin, A.Volkmann, D.Fisher, A.Nalca. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine 2009; 27:5496-504; PMID:19632316; http://dx.doi.org/10.1016/j.vaccine.2009.06.105
19. J.Stabenow, R.M.Buller, J.Schriewer, C.West, J.E.Sagartz, S.Parker. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus. J Virol 2010; 84:3909-20; PMID:20130052; http://dx.doi.org/10.1128/JVI.02012-09
20. M.B.Townsend, M.S.Keckler, N.Patel, D.H.Davies, P.Felgner, I.K.Damon, K.L.Karem. Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations. J Virol 2013; 87:900-11; PMID:23135728; http://dx.doi.org/10.1128/JVI.02089-12
21. S.E.Frey, P.L.Winokur, H.Hill, J.B.Goll, P.Chaplin, R.B.Belshe. Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naive individuals. Vaccine 2014; 32:2732-9; PMID:24607004; http://dx.doi.org/10.1016/j.vaccine.2014.02.043
22. J.D.Troy, H.R.Hill, M.G.Ewell, S.E.Frey. Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE((R)) smallpox vaccine. Vaccine 2015; 33:5425-31; PMID:26319063; http://dx.doi.org/10.1016/j.vaccine.2015.08.032
23. J.H.Draize, G.Woodard, H.O.Calvery. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Therapies 1944; 82:377-90
24. L.Angervall, E.Carlstrom. Theoretical criteria for the use of relative organ weights and similar ratios in biology. J Theoret Biol 1963; 4:254-259; PMID:5875198